Carboplatin, Gemcitabine and Durvalumab Treatment Protocol for Bladder Cancer

Drugs and Mechanism of Action

• Gemcitabine: Antimetabolite; inhibits DNA synthesis.
• Carboplatin: Platinum compound; inhibits replication through DNA crosslinks (less nephrotoxicity/ototoxicity than cisplatin, with a tendency toward more thrombocytopenia ).
• Durvalumab (Imfinzi): Enhances T-cell activation through PD-L1 blockade, strengthening the immune-mediated antitumor response.

The combination aims for rapid tumor burden reduction through chemotherapy and lasting immune control through immunotherapy.

Indication and Regulatory Status

• FDA approval (perioperative): only cisplatin + gemcitabine + durvalumab (neoadjuvant) → surgery → adjuvant durvalumab; March 28, 2025was the approval date. The carboplatin version is not approved.
• Guideline framework (2025): The “preferred” perioperative approach is cisplatin-based. Carboplatin use is considered individually when cisplatin is contraindicated.
• Evidence note: Durvalumab + gemcitabine with carboplatin arms have been studied across the urothelial cancer spectrum in phase II or exploratory trials, including upper tract cohorts.

Patient Selection (Practical)

• Cisplatin-ineligible urothelial bladder cancer (e.g., Ccr <60 mL/min, auditory neuropathy, severe comorbidities).
• Stage context: Perioperative assessment in muscle-invasive bladder cancer should prioritize a clinical trial ; in metastatic/migrating disease, individualize with institutional board approval.
• Performance: ECOG 0–2 (according to center protocol).

Dosing and Schedule 

In the Neoadjuvant or Metastatic Setting

Cycle: 21 days = 1 cycle |   Total: 4 cycles (neoadjuvant example). In metastatic disease, 4–6 cycles according to response/tolerance.

Surgery (Perioperative scenario)

Radical cystectomy (pelvic LND in appropriate cases).

Adjuvant Phase 

• Durvalumab: 1500 mg IV every 4 weeks; a total of 8 cycles (≤12 months).

Infusion Times (Estimated)

• Day 1: Up to ~3–4 hours with premedication + fluids.
• Day 8: Usually ~30 min (gemcitabine alone).
• Actual times vary by center and tolerance.

Note: Doses are provided as “institutional examples”; they must be finalized according to the center’s protocol and board approval.

SGK / Status in Türkiye

• Gemcitabine & Carboplatin:Reimbursed by SGK. 
• Durvalumab (Imfinzi):Licensed in Türkiye; however, the perioperative muscle-invasive bladder cancer indication is not yet reimbursed by SGK.
• Durvalumab (Imfinzi) price:74,425.28 TL for a 500 mg vial and 17,856.38 TL for a 120 mg vial. 

Special Situations Requiring Attention

Hematological Toxicity

• Thrombocytopenia (more pronounced with carboplatin), neutropenia, anemia.
• Complete blood count before each cycle; G-CSF and dose modification if needed.

Kidney / Liver

• Carboplatin dosing is based on GFR; renal function should be monitored regularly.
• Adjust Gemcitabine doses for elevated hepatic enzymes.

Immune-Mediated Events (Durvalumab)

• Thyroid dysfunction, hepatitis, pneumonitis, colitis, dermatitis → guideline-based steroid management.

Nausea/Emetogenicity

• Carboplatin is moderately emetogenic; plan appropriate antiemetic prophylaxis.

Side Effects (Expected)

• Nausea, vomiting; loss of appetite, fatigue.
• Hematological: thrombocytopenia (>carboplatin), neutropenia, anemia; fever.
• Laboratory: creatinine/GFR changes; liver enzymes.
• Immune-mediated: thyroid disorders, skin rash/itching, rarely pneumonitis.
• GI/urinary complaints such as urinary tract infection, diarrhea/constipation.

Evidence and Context

• FDA (28 Mar 2025): Perioperative cisplatin + gemcitabine + durvalumab (neoadjuvant) → surgery → adjuvant durvalumab is approved.
• NCCN 2025: The preferred perioperative approach is “cisplatin-based.”
• Carboplatin-arm data: Durvalumab + gemcitabine with carboplatin has been investigated in phase II/exploratory trials (including upper tract cohorts); institution-based assessment is recommended.